hVIVO PLC - hVIVO launches unified brand identity
hVIVO plc
("hVIVO", the "Company" or the "Group")
hVIVO launches unified brand identity reflecting strategic transformation into integrated clinical development partner
Reinforces establishment of purpose-built, fully integrated platform, designed to accelerate pathway to clinical proof-of-concept
The rebrand follows the successful integration of Venn Life Sciences, CRS and Cryostore and marks the completion of the Group's transition from a specialist services provider to a fully integrated platform supporting clients from preclinical strategy through to Phase II and selected Phase III programmes. All operating companies will now trade under the hVIVO brand, simplifying the Group's structure and re-enforcing its single partner model. This provides clients with one integrated team, clear continuity across the development pathway.
The Group now operates through four integrated service lines, forming a purpose-built platform designed to generate faster, more decisive, high-quality human data, reducing complexity, minimising handoffs and enabling novel, more efficient trial designs:
· Consulting: provides early stage scientific, regulatory and development strategy support across the drug development lifecycle, enabling clients to design robust programmes and generate decision ready data from the outset. Drawing on deep expertise in early drug development, clinical pharmacology and biostatistics, teams support sponsors from pre-clinical planning through to clinical proof-of-concept, including study design, dose rationale and regulatory strategy;
· Clinical Trials: provides specialist early phase clinical trial services through owned and controlled clinical research sites, supporting studies from First-in-Human through to Phase II and selected Phase III programmes. It includes full Phase I and II CRO services, complemented by Phase II and III site services delivered within hVIVO's facilities. This model enables greater operational control, accelerates timelines and ensures reliable recruitment across healthy volunteers, patient populations and specialist cohorts;
· Human Challenge Trials: enables rapid and controlled evaluation of vaccines and therapeutics by exposing healthy volunteers to well characterised pathogens under carefully controlled conditions. These studies allow earlier assessment of efficacy, biological response and dose selection compared to traditional field-based studies;
· Laboratories: provide specialist virology, immunology and biomarker analysis to support early phase clinical development, human challenge trials and standalone laboratory programmes. Closely integrated with clinical operations, services include assay development, sample analysis and data interpretation and biobanking with long-term storage capabilities.
Yamin 'Mo' Khan, Chief Executive Officer of hVIVO, said: "This rebrand reflects our strategic transformation into a purpose-built, full-service international clinical development partner, addressing the industry's need for faster, high-quality data that can de-risk drug development.
"By bringing together consulting, clinical trials, human challenge trials and laboratories into a single, unified platform, we offer clients a seamless pathway from pre-clinical strategy to clinical proof-of-concept, delivered by one expert partner. Our unified brand reinforces the strength of our integrated model, proprietary infrastructure and deep scientific expertise, and our ability to ultimately help pharmaceutical and biotech companies bring important medicines to patients faster."
For further information please contact:
|
hVIVO plc |
+44 (0)20 7756 1300 |
|||
|
Yamin 'Mo' Khan, Chief Executive Officer |
|
|||
|
|
|
|||
|
Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker) |
+44 (0)20 7220 0500 |
|||
|
|
|
|||
|
|
|
|||
|
Peel Hunt LLP (Joint Broker) |
+44 (0)20 7418 8900 |
|||
|
James Steel, Dr |
|
|||
|
|
|
|||
|
Davy (Joint Broker) |
+353 (0) 1 679 6363 |
|||
|
|
|
|||
|
|
|
|||
|
ICR Healthcare (Financial PR & IR)
|
||||

Notes to Editors
hVIVO plc (AIM: HVO) is a purpose-built, full-service international clinical development partner and the global leader in human challenge trials, serving seven of the world's ten largest biopharma companies.
The Company has an end-to-end platform designed to bring important medicines to patients faster: spanning preclinical strategy, first‑in‑human studies, Phase II patient trials and specialist laboratory services, delivered through wholly owned sites and laboratories across the
With a combined Group heritage of more than 100 years, hVIVO delivers an accelerated pathway to clinical proof-of-concept through four integrated service pillars: Consulting, Clinical Trials, Human Challenge Trials, and Laboratories.
· Consulting provides expert-led pre-clinical and clinical strategy, encompassing non-clinical, clinical, CMC, pharmacokinetics, data management, biostatistics, and regulatory support to guide trial design, execution, and interpretation.
· Clinical Trials offers Phase I/II CRO services, Phase II/III site services across the
· Human Challenge Trials leverages hVIVO's state-of-the-art quarantine facility in
· Laboratories provides cutting-edge virology and immunology laboratory services, including biobanking and sample storage, supporting both challenge trials and standalone client studies.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE